Pulmozyme

BeschreibungDornase alfa, the highly purified solution of recombinant human deoxyribonuclease I (rhDNase) produced by genetic engineering technology, was launched in 1994 first in the U.S.A. and shortly after in 7 other countries as the first new drug released in 30 years for the treatment of cystic fibrosis. Dornase alfa is effective in liquefying secretions from the lungs of cystic fibrosis patients by cleaving the extracellular DNA in purulent sputum and therefore reducing the viscoelasticity of the secretion. It also lessens dyspnea, improves lung function, reduces cough severity and frequency, increases the perception of well-being for the patients with cystic fibrosis related symptoms, and has excellent safety profile. Significant benefits have been reported in trials for the treatment of chronic obstructive pulmonary disease and acute infectious exacerbation of chronic bronchitis.

VerwendenCystic fibrosis therapy adjunct.